CytoMed Therapeutics Long Term Debt

The latest long-term debt for GDTC is $420K as of December 2025. That compares with $310K in the prior-year period — up 38.0% year over year. Investors often review this figure alongside CytoMed Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GDTC's long-term debt moved from $310K to $420K — a 38.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CytoMed Therapeutics's operating scale or balance-sheet position.

A long-term debt figure of $420K for GDTC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GDTC's long-term debt ($420K), review year-over-year change from $310K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.